Epizyme, Inc. (EPZM) Director David M. Mott Acquires 200,000 Shares of Stock
Epizyme, Inc. (NASDAQ:EPZM) Director David M. Mott purchased 200,000 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were purchased at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Epizyme, Inc. (EPZM) opened at 17.85 on Tuesday. The company’s market capitalization is $1.04 billion. Epizyme, Inc. has a 12 month low of $8.38 and a 12 month high of $18.80. The stock’s 50 day moving average price is $15.27 and its 200-day moving average price is $15.22.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.08. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. Epizyme’s quarterly revenue was up 2027.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.49) EPS. On average, equities research analysts predict that Epizyme, Inc. will post ($2.39) EPS for the current fiscal year.
WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/epizyme-inc-epzm-director-david-m-mott-acquires-200000-shares-of-stock.html.
A number of brokerages have recently commented on EPZM. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Monday, August 7th. Leerink Swann reissued an “outperform” rating and set a $28.00 price target (down from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $20.00 price target on Epizyme and gave the company a “buy” rating in a research note on Saturday, August 5th. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. Finally, BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Epizyme currently has a consensus rating of “Buy” and an average price target of $23.38.
A number of hedge funds have recently modified their holdings of EPZM. Legal & General Group Plc boosted its holdings in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 795 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in Epizyme during the 1st quarter valued at about $175,000. BB&T Securities LLC purchased a new stake in Epizyme during the 2nd quarter valued at about $181,000. Trexquant Investment LP purchased a new stake in Epizyme during the 2nd quarter valued at about $184,000. Finally, SG Americas Securities LLC boosted its holdings in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 6,072 shares during the period. Institutional investors own 83.74% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.